107 results
Page 4 of 6
8-K
EX-99.2
zucsvccchajy
4 Mar 20
Moleculin Issues Video Shareholder Letter
7:31am
8-K
EX-99.1
egzaij2xadlkujy8fh
20 Feb 20
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date
7:32am
424B5
ulls2
6 Feb 20
Prospectus supplement for primary offering
5:08pm
8-K
EX-99.1
vropvjq
3 Feb 20
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
7:32am
8-K
EX-99.1
jay3fal30nic
13 Jan 20
Regulation FD Disclosure
7:01am
8-K
EX-99.1
2x8je15md8 rssu
19 Dec 19
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
4:06pm
8-K
EX-99.1
qm2fg4089b
4 Dec 19
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
7:31am
8-K
EX-99.1
rax2x vaiuq222r5
12 Nov 19
Results of Operations and Financial Condition
6:33am
8-K
EX-99.1
cej5hu
29 Oct 19
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
19hhbzfh
29 Oct 19
Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7:31am
8-K
EX-99.1
frdjzqay77cdcdutb
16 Aug 19
Results of Operations and Financial Condition
5:18pm
8-K
EX-99.1
xkwsk5fk51y
6 Aug 19
Regulation FD Disclosure
7:48am
8-K
EX-1.1
f1rqdkvbu5c27t8jt
24 Jul 19
Entry into a Material Definitive Agreement
7:30am
8-K
e1z7o6hu41iuov5bqxes
12 Jul 19
Departure of Directors or Certain Officers
4:03pm
8-K
EX-99.1
rah yhl9xz2
31 May 19
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
8k32wctq 3a5l08oh54
14 May 19
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
jcdgt4w8
7 May 19
Regulation FD Disclosure
4:34pm